Migraine prophylaxis: less evidenced options
Evidence-based neurology checklist on migraine prophylaxis: less evidenced options: Less evidenced agents Lisinopril: 20mg daily Atogepant: a CGRP-receptor antagonist Magnesium: 400-600mg daily Melatonin: 2mg daily: maintenance is 4-8mg daily Memantine 10-20mg daily Nortriptyline: the starting…
Less evidenced agents
- Lisinopril: 20mg daily
- Atogepant: a CGRP-receptor antagonist
- Magnesium: 400-600mg daily
- Melatonin: 2mg daily: maintenance is 4-8mg daily
- Memantine 10-20mg daily
- Nortriptyline: the starting dose is 10mg daily: increase by 10mg weekly to 25-75mg nocte
- Riboflavin: 400mg daily
- Cyproheptadine: 4-12mg daily
- Venlafaxine: starting dose is 37.5mg daily: aim for 75-150mg daily
- Clonidine
- Guanfacine
- Methysergide
- Nebivolol
- Pindolol
Insufficient evidenced agents
Investigational agents
Acronym
References
- Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol 2021; 17:501-514.
- Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337-1345.
- MacGregor EA, Steiner TJ, Davies PTG. British Association for the Study of Headaches (BASH). Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache. September 2010.
- Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 2018; 15:313-323.
- Hovaguimian A, Roth J. Management of chronic migraine. BMJ 2022; 379:e067670.
- And 14 more. Subscribe to see the full list
